BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17223446)

  • 1. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment.
    Muggia FM
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S18-24. PubMed ID: 17223446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
    Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
    J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for ovarian cancer.
    Kelland LR
    Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
    Fiorentini G; Filippeschi M; Turrisi G; Mambrini A; Giannessi PG; D'Alessandro M; Rossi S; Dentico P; Guadagni S; Cantore M; Madrigali A
    In Vivo; 2009; 23(2):317-21. PubMed ID: 19414421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer.
    Markman M
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S3-7. PubMed ID: 17223444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal chemotherapy for women with ovarian cancer: nursing care and considerations.
    Potter KL; Held-Warmkessel J
    Clin J Oncol Nurs; 2008 Apr; 12(2):265-71. PubMed ID: 18390462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.
    de Bree E; Theodoropoulos PA; Rosing H; Michalakis J; Romanos J; Beijnen JH; Tsiftsis DD
    Cancer Treat Rev; 2006 Oct; 32(6):471-82. PubMed ID: 16942841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life.
    Alberts DS; Delforge A
    Semin Oncol; 2006 Dec; 33(6 Suppl 12):S8-17. PubMed ID: 17223445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complications associated with intraperitoneal chemotherapy catheters.
    Makhija S; Leitao M; Sabbatini P; Bellin N; Almadrones L; Leon L; Spriggs DR; Barakat R
    Gynecol Oncol; 2001 Apr; 81(1):77-81. PubMed ID: 11277654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
    Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
    Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Fung-Kee-Fung M; Provencher D; Rosen B; Hoskins P; Rambout L; Oliver T; Gotlieb W; Covens A;
    Gynecol Oncol; 2007 Jun; 105(3):747-56. PubMed ID: 17368522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intraperitoneal chemotherapy in ovarian carcinoma].
    Piura B
    Harefuah; 2001 Sep; 140(9):844-9, 894, 893. PubMed ID: 11579736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer.
    Almadrones L
    Clin J Oncol Nurs; 2007 Apr; 11(2):211-6. PubMed ID: 17573270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of chemotherapy in the management of epithelial ovarian cancer.
    Reed NS; Sadozye AH
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):139-47. PubMed ID: 15757446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view.
    Vergote I; Amant F; Leunen K; Cadron I; Van Gorp T; Neven P; Berteloot P
    Oncologist; 2008 Apr; 13(4):410-4. PubMed ID: 18448555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy: implications beyond ovarian cancer.
    Marin K; Oleszewski K; Muehlbauer P
    Clin J Oncol Nurs; 2007 Dec; 11(6):881-9. PubMed ID: 18063547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.